文献速递甲状腺疾病垂体与肾上腺疾病性腺与生殖内分泌

接受药物治疗的注意缺陷多动障碍儿童的生长激素与甲状腺功能

Growth Hormone and Thyroid Function in Children With Attention Deficit Hyperactivity Disorder Undergoing Drug Therapy.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

这项前瞻性研究自然观察了118例初治注意缺陷多动障碍(ADHD)儿童12个月,其中22例未用药,39例接受低剂量短效哌甲酯(14 ± 6.7 mg/日)、40例接受渗透泵口服系统长效哌甲酯(32 ± 9.6 mg/日)、17例接受托莫西汀(29.2 ± 9.7 mg/日)。四组间胰岛素样生长因子1(IGF-1)、胰岛素样生长因子结合蛋白3(IGFBP-3)、催乳素、促甲状腺激素(TSH)、三碘甲状腺原氨酸(T3)、甲状腺素(T4)、游离T4的变化趋势相似;IGF-1变化与身高、体重变化正相关;哌甲酯组体重增长少于未用药组;哌甲酯剂量与体重比值与身高增量呈负相关。结论认为本研究使用的低剂量ADHD药物1年内未引起甲状腺或生长激素变化,但仍应密切监测患儿生长和药物剂量合理性。

要点

  • 四组间IGF-1、IGFBP-3、催乳素、TSH、T3、T4、游离T4水平变化趋势相似。
  • IGF-1变化与所有ADHD儿童的身高和体重变化正相关。
  • 哌甲酯组体重增长少于未用药组,哌甲酯剂量与体重比值与身高增量负相关。

核心结论

  • 本研究使用的低剂量ADHD药物在1年疗程内未引起甲状腺或生长激素变化,但仍应密切监测患儿生长和药物剂量合理性。

研究设计与样本

  • 前瞻性自然观察研究,共纳入118例初治ADHD儿童,观察12个月。
  • 22例未用药,39例接受低剂量短效哌甲酯(14 ± 6.7 mg/日),40例接受渗透泵口服系统长效哌甲酯(32 ± 9.6 mg/日),17例接受托莫西汀(29.2 ± 9.7 mg/日)。
  • 基线和终点(第12个月)采血测定IGF-1、IGFBP-3、催乳素、TSH、T3、T4和游离T4。

主要发现

  • 四组间IGF-1、IGFBP-3、催乳素、TSH、T3、T4和游离T4水平的变化趋势相似。
  • 所有ADHD儿童中,血清IGF-1水平变化与身高和体重变化呈正相关。
  • 接受哌甲酯治疗的患者体重增长少于未用药组。
  • 哌甲酯剂量与体重比值与身高增量呈负相关。

临床怎么用

  • 原文未据此给出推荐,作者认为应密切监测患者的生长和药物剂量的合理性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The trends in hormone indices of children with attention deficit hyperactivity disorder (ADHD) who received long-term medication treatment remains controversial. OBJECTIVE: This prospective study aimed to examine the changes in the growth hormone and thyroid hormone systems among children with ADHD undergoing various medication treatments. METHODS: In total, 118 children who were diagnosed with ADHD and were drug-naive were observed naturalistically over 12 months. Of them, 22 did not receive any medication, while 39, 40, and 17 were treated with low doses of short-acting methylphenidate (MPH) (14 ± 6.7 mg/day), osmotic-release oral system (OROS) long-acting MPH (32 ± 9.6 mg/day), and atomoxetine (29.2 ± 9.7 mg/day), respectively. Blood samples were obtained at both the baseline and the endpoint (month 12) to measure serum levels of insulin-like growth factor 1 (IGF-1), IGF binding protein 3 (IGFBP-3), prolactin, thyroid-stimulating hormone (TSH), triiodothyronine (T3), thyroxine (T4), and free T4. RESULTS: Trends for IGF-1, IGFBP-3, prolactin, TSH, T3, T4, and free T4 levels were similar among the 4 groups. Changes in serum levels of IGF-1 were positively correlated with changes in height and weight of all the children with ADHD. However, patients who received MPH treatment had less body weight gain than the nonmedicated group. The ratio of MPH doses to body weight was inversely correlated with the increment in height. CONCLUSION: There were no changes in thyroid or growth hormones associated with the low doses of ADHD medications used in this study within 1 year's duration. Nonetheless, patients' growth and the appropriateness of drug dosage should be closely monitored.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Wang LJ, Huang YH, Chou WJ, et al. Growth Hormone and Thyroid Function in Children With Attention Deficit Hyperactivity Disorder Undergoing Drug Therapy. J Clin Endocrinol Metab. 2022. PMID: 35262170. doi:10.1210/clinem/dgac139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。